TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
US FDA approval based on NEURO-TTRansform Phase III results
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Subscribe To Our Newsletter & Stay Updated
